Answers are grounded in this paper and cite their sources.
Systematic approach improves patient selection and monitoring in advanced therapies for IBD, suggesting better outcomes.
Key Takeaways: • Deprescribing advanced therapies is a viable option for carefully-selected patients living with IBD. • We propose a systematic approach for deprescribing advanced therapies in IBD, which comprises strategic patient selection, comprehensive risk assessment, shared decision-making, rigorous monitoring, and a pre-defined rescue strategy. • Further research is needed to improve patient selection tools, optimize monitoring techniques, and clarify deprescribing strategies for newer agents.
No takes yet. Share an insight, caveat, or question.
Squirell et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: